Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.
about
Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfallsNew molecular insights into peripheral T cell lymphomasDiagnosis and management of extranodal NK/T cell lymphoma nasal type.Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomasGene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphomaToward a Biology-Driven Treatment Strategy for Peripheral T-cell LymphomaWhole genome sequencing of Ethiopian highlanders reveals conserved hypoxia tolerance genesIntegrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma.Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitorsExtranodal NK/T-cell lymphoma: toward the identification of clinical molecular targetsClinicopathological analysis of 17 primary cutaneous T-cell lymphoma of the γδ phenotype from JapanPRDM1 is a tumor suppressor gene in natural killer cell malignancies.Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma.Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.Diagnostic and Biological Significance of KIR Expression Profile Determined by RNA-Seq in Natural Killer/T-Cell Lymphoma.Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).State of the art in natural killer cell malignancies.Extranodal nasal type natural killer/T-cell lymphoma of testis: report of seven cases with review of literature.Pathogenesis and treatment of leukemia: an Asian perspective.ENMD-2076 for hematological malignancies.Primary cutaneous CD56 positive lymphoma: a diagnostic conundrum in an unusual case of lymphoma.Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved.Cutaneous EBV-positive γδ T-cell lymphoma vs. extranodal NK/T-cell lymphoma: a case report and literature review.Whole genome profiling and other high throughput technologies in lymphoid neoplasms--current contributions and future hopes.Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders.Peripheral T cell lymphoma in Asia.Molecular genetics of peripheral T-cell lymphomas.Genomic expression profiling of NK cells in health and disease.Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications.The role of alisertib in treatment of peripheral T-cell lymphomas.Molecular Pathogenesis of Peripheral T Cell Lymphoma.The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project.Novel targets for natural killer/T-cell lymphoma immunotherapy.Whole transcriptome analysis reveals dysregulated oncogenic lncRNAs in natural killer/T-cell lymphoma and establishes MIR155HG as a target of PRDM1.JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.Differential expression of aurora-A kinase in T-cell lymphomas.The diagnosis and management of NK/T-cell lymphomas.Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).
P2860
Q17149636-56D32776-3111-4466-84BB-5FF28E91B483Q54872411-7D72CC4F-90BA-4DFD-A234-CC115E60A2EBQ54897515-B2474D86-2BA6-403D-8572-1FD306A01369Q54899458-EDE17321-88FC-4E25-9A41-95D1BE3EFD2AQ54899912-7534911D-D9F4-47D9-81CA-67BC6991EBFAQ54930662-5A1BA530-64F9-4EF8-BE08-0BF8BCA09040Q54955063-611779A2-27CD-4588-BA43-F025F340F98BQ54955064-4C497E01-A5B6-4C42-9341-C57703075738Q54955067-908CE8CC-FC81-44BF-94A0-F62BE3863E83Q54955073-7A6A3DF0-FE49-462F-AC91-089229D98C17Q54955074-7F97AD33-306D-4F05-822A-A3D38B755B2BQ54955077-A2829E0B-B419-4627-B687-C04758CCE8B0Q54995532-A670EA8A-121A-4642-BC18-720D5E31563C
P1343
Q27004241-864CFCB6-0561-4D60-BED9-7DF1CD3D19BBQ27026081-3C2224CC-9BDA-4AA1-8BB0-247EFC10CED6Q30249309-0E0EA2C4-0BC6-4F9A-9C7B-E075E700EF41Q33410380-76835C7F-CE09-44EC-8621-56B4A44B72E0Q33585243-57E6BF02-FE8C-47DF-82A6-8DBFB224BD86Q33670421-23125EC7-30A0-440A-8867-7F3BF9A954C5Q33745301-BC08EB3F-E4F3-4447-BB40-0F2B4D075144Q33945848-C2361A0E-01C8-419B-B3BF-D1140E2AF17CQ34576589-E7BEDD4D-589A-41A6-97A3-E86900ABAB68Q34898306-70591A32-2EA6-48F5-9E82-FF79C620625AQ35051861-4F606244-091E-479A-86A7-CAF4F612D65FQ35647475-66A43CE9-88E5-418F-AD70-E082E3026592Q35859357-3E37F6F2-6A91-49E8-B41C-ECF79E3B900AQ36915132-09A2CBDF-93DF-47F0-AF5B-6B63B47124D3Q36990211-C8B3D439-6B4F-47F4-BB08-6A1439DF9AFDQ37187642-572634BF-2808-4A41-95E9-2CBABE5054A8Q37863688-CE280B7A-9B89-4C18-BDF2-00D1575D79BCQ37927210-DC49440D-20A1-40F5-9690-57EBC6BB8AA0Q37963470-7066CA35-3B32-4340-8D1C-2F6D0A6C905EQ37982115-3978D27F-2046-4D84-B071-692D26C8C190Q37991379-FC1E96EB-9132-43E5-B436-D32B7B8208E0Q38004052-4835C52B-1F24-4411-A5D6-97D79D5313E1Q38043974-1243EFD4-BDC0-4851-A6BA-23DD0376C91EQ38067483-E56B7633-E44F-4BC4-A417-76EA23269C09Q38071077-3B40D6E5-9834-45FC-8CC1-84173893E9F3Q38179491-23846E10-61B1-4CE8-AC54-E90C00392B74Q38183756-3619F32A-0921-4C36-B4D8-3258FB1E7FE8Q38183757-9619AE65-1660-4380-A4E4-1A7F09742013Q38283442-40F00AAC-2F2B-4A4A-915C-8EA07C3BF71CQ38289038-C859F7DB-328D-4C2F-9141-E89C267BB45BQ38581916-DF2A1E5F-6B9B-4A11-B86F-269ACD2824A0Q38597997-BDC2373B-D029-4A77-84F6-A4B285C917E7Q38602677-A00AB7EF-BD45-426A-B801-EFD2DD85DA64Q38661106-E568DC12-5CB6-4B96-A3B0-E1B2E81F75AFQ38705023-CBF73EF3-0076-4298-806B-841584711C57Q39149556-AA404A79-C16D-4950-97D2-26A913FDB1A7Q39194122-0A6FB5B1-BDC9-46CD-9B37-F0A6C0A2C7DDQ39243241-84542DE6-338F-4EA3-A0B8-158263CA17B6Q39244395-FDFA7C53-2637-416E-8642-1EC28BE7B83FQ39284101-A1201CB4-B202-4D97-B4F8-3801803F0A6D
P2860
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Natural killer cell lymphoma s ...... a kinase A inhibitor in vitro.
@en
Natural killer cell lymphoma s ...... a kinase A inhibitor in vitro.
@nl
type
label
Natural killer cell lymphoma s ...... a kinase A inhibitor in vitro.
@en
Natural killer cell lymphoma s ...... a kinase A inhibitor in vitro.
@nl
prefLabel
Natural killer cell lymphoma s ...... a kinase A inhibitor in vitro.
@en
Natural killer cell lymphoma s ...... a kinase A inhibitor in vitro.
@nl
P2093
P2860
P4510
P356
P1433
P1476
Natural killer cell lymphoma s ...... a kinase A inhibitor in vitro.
@en
P2093
A Chowdhury
D D Weisenburger
G Srivastava
International Peripheral T-cell Lymphoma Project
J Armitage
P2860
P2888
P304
P356
10.1038/LEU.2010.255
P50
P577
2010-11-05T00:00:00Z
P6179
1008761554